ABSTRACT
We studied the expression of oncogenes and tumor-suppressor genes in human endometriosis in a retrospective pilot study. Sixteen patients with histologically verified pelvic endometriosis at the university-based tertiary care referral center were studied. Immunohistochemical determination of c-myc, c-erb-B2, nm23 and p53 expression in archival, paraffin-embedded pathological samples were used from patients operated upon for pelvic endometriosis. c-myc was expressed in 8/15 cases (53.3%). nm23 was expressed in 7/16 cases (43.7%). c-erb-B2 and p53 reactivity was undetectable in the samples studied. The c-myc oncogene and nm23 are overexpressed in many cases of endometriosis, and may play a still undefined role in its pathogenesis. Immuno-histochemistry is a useful tool for the study of oncogenic activation in this disease.
Subject(s)
Endometriosis/pathology , Genes, Tumor Suppressor , Genes, erbB-2 , Genes, myc , Monomeric GTP-Binding Proteins , Nucleoside-Diphosphate Kinase , Proto-Oncogene Proteins c-myc/analysis , Receptor, ErbB-2/analysis , Transcription Factors/analysis , Uterine Diseases/pathology , Biopsy , Endometriosis/genetics , Endometriosis/metabolism , Female , Genes, p53 , Humans , NM23 Nucleoside Diphosphate Kinases , Proto-Oncogene Proteins c-myc/biosynthesis , Receptor, ErbB-2/biosynthesis , Transcription Factors/biosynthesis , Tumor Suppressor Protein p53/analysis , Tumor Suppressor Protein p53/biosynthesis , Uterine Diseases/genetics , Uterine Diseases/metabolismABSTRACT
A case of carcinoma of the prostate metastatic to breast is reported. We highlight its rarity, its relationship with estrogen treatment, and the poor prognosis of this condition which develops in the end stages of metastatic carcinoma of prostate.
Subject(s)
Adenocarcinoma/secondary , Breast Neoplasms/secondary , Prostatic Neoplasms , Adenocarcinoma/drug therapy , Adenocarcinoma/pathology , Aged , Breast Neoplasms/drug therapy , Breast Neoplasms/pathology , Estrogens/therapeutic use , Humans , MaleABSTRACT
We report on a case of primary transitional cell carcinoma of the prostate associated with focal prostatic carcinoma, incidentally discovered after TUR of the prostate. An underlying bladder tumor was discarded by randomized TUR of the bladder and serial cytologic analyses.
Subject(s)
Adenocarcinoma , Carcinoma, Transitional Cell , Neoplasms, Multiple Primary , Prostatic Neoplasms/pathology , Adenocarcinoma/radiotherapy , Adenocarcinoma/surgery , Aged , Carcinoma, Transitional Cell/radiotherapy , Carcinoma, Transitional Cell/surgery , Combined Modality Therapy , Humans , Male , Neoplasms, Multiple Primary/radiotherapy , Neoplasms, Multiple Primary/surgery , Prostatectomy , Prostatic Neoplasms/radiotherapy , Prostatic Neoplasms/surgeryABSTRACT
We report on a 54-year-old male patient with Leydig cell tumor of testis, an incidental finding following orchiectomy for a testicular tumor. The pathological findings met the established histologic criteria for a benign tumor. The patient required no other treatment. The results of hormonal analyses were hormonal. We discuss recently proposed histologic and hormonal criteria to distinguish the benign from the malignant form of this tumor type. The foregoing are useful in determining the therapeutic approach.
